- Home
- GIGM vs ALLR Comparison
GIGM vs ALLR Comparison
Compare GIGM & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- ALLR
- Stock Information
- Founded
- GIGM 1998
- ALLR 2004
- Country
- GIGM Taiwan
- ALLR United States
- Employees
- GIGM N/A
- ALLR N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- ALLR Health Care
- Exchange
- GIGM Nasdaq
- ALLR Nasdaq
- Market Cap
- GIGM 17.8M
- ALLR 20.2M
- IPO Year
- GIGM 2000
- ALLR N/A
- Fundamental
- Price
- GIGM $1.58
- ALLR $1.31
- Analyst Decision
- GIGM
- ALLR Strong Buy
- Analyst Count
- GIGM 0
- ALLR 1
- Target Price
- GIGM N/A
- ALLR $9.25
- AVG Volume (30 Days)
- GIGM 6.8K
- ALLR 255.7K
- Earning Date
- GIGM 10-30-2025
- ALLR 11-14-2025
- Dividend Yield
- GIGM N/A
- ALLR N/A
- EPS Growth
- GIGM N/A
- ALLR N/A
- EPS
- GIGM N/A
- ALLR N/A
- Revenue
- GIGM $3,397,000.00
- ALLR N/A
- Revenue This Year
- GIGM N/A
- ALLR N/A
- Revenue Next Year
- GIGM N/A
- ALLR N/A
- P/E Ratio
- GIGM N/A
- ALLR N/A
- Revenue Growth
- GIGM 10.11
- ALLR N/A
- 52 Week Low
- GIGM $1.38
- ALLR $0.61
- 52 Week High
- GIGM $1.89
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- GIGM 39.01
- ALLR 43.27
- Support Level
- GIGM $1.58
- ALLR $1.09
- Resistance Level
- GIGM $1.66
- ALLR $1.45
- Average True Range (ATR)
- GIGM 0.04
- ALLR 0.10
- MACD
- GIGM -0.01
- ALLR -0.01
- Stochastic Oscillator
- GIGM 21.41
- ALLR 45.00
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.